Thus, in a way to assist the repair process, several works have focused on the administration of exogenous stem cells. Surprisingly, the administration of adult stem cell in several experimental diseases have showed to improve in its clinical outcome and moreover amelioration of tissue architecture. However, the mechanism of action that leads to this improvement is not well defined. Fusion of dying cells with MSC, differentiation of MSC to other cell types or paracrine action, by secretion of several bioactive factors are the main mechanism of action suggested. New mechanisms have also been suggested with the knowledge of microRNA. These topics will be better explained in the next sections.
Animals models of human diseases: kidney, heart, CNS, liver, lung and pancreas
The main experimental models treated with mesenchymal stem cells are summarized in the next table (Table I) . Immunomodulation and paracrine action (32) Rat MSC, 1x10 5 cell/rat, e.v., 1 week after 5/6 nephrotomy MSC engraftment and paracrine action (33) Chronic Kidney Injury (unilateral ureteral obstruction)
Experimental
Human MSC, 1x10 6 cell/rat, intra-arterially, after ureter obstruction (63) (64) (65) (66) . Both mechanical and electrical stimulation have been applied separately and combined with soluble factors to facilitate MSC differentiation (67) . The criteria for differentiation need to be rigorously defined. It appears difficult to ascertain about differentiation process. Some markers are specific for certain cells; however they do not have functional relation. In addition these markers are not unique to characterize a specific cell. Delorme et al have found that MSC express cytoskeletal proteins usually expressed in neural stem cells (nestin), hepatocytes (cytokeratin-8 and -18), biliary cells (cytokeratin-19), and sarcomeric muscle (troponins, a-C-actin), without the expression of proneural or neuronal, prohepatocytic, or myogenic key transcription factors (68) . Although cytoskeletal markers remain adequate indicators of a differentiation pathways, there are numerous exceptions to the rule, such as the expression of cytokeratin-18 in vascular smooth muscle cells in the synthetic phase and other similar misleading expression factors as reported by Montzka (69) . Some of the observed differentiations may also result from reprogramming. Dezawa and colleagues have shown that rodent and human bone marrow MSC can be reprogrammed into cells with skeletal muscle potential after specific treatment comprising first cytokines and then gene transfer of the notch intracellular domain (70) . Differentiation induction can be also marked by the decline of one factor at the expense of the other, like runt-related transcription factor-2 (RUNX2) downregulation and peroxisome proliferator-activated receptor-g (PPARγ) upregulation in the adipogenic condition, which remains to be tested at the single cell level (71) . It has been shown that MSC of various species may undergo myogenic differentiation (72, 73) . In a mouse model of myocardial infarction it has been seen that MSCs are capable of engrafting in the site of injury and differentiating into cardiomyocyte-like cells expressing typical cardiomyocyte markers (74) . Another study showed that in mice undergoing cisplatin-mediated acute renal failure, systemic injection of MSCs resulted in accumulation of MSC in the kidney and differentiation into tubular epithelial cells that exhibited the characteristic brush border of the proximal tubule cells (55) . Besides, there have been a number of reports suggesting that MSC differentiate into epidermal keratinocytes and endothelial cells in vivo (75, 76) . In vivo, adipose-derived MSC can migrate through the hemato-encephalic barrier after adhesion to the endothelium (77), and they can differentiate into neuroglial lineages after intraventricular in utero injection in rats (78) . However, in humans there is no evidence concerning the neural regenerative potential of MSC. MSC obtained from different tissue sources show some differences regarding differentiation potential and gene expression profiles. Thus, it has become clear that the microenviroment in which MSCs are transplanted, growth factors and local cellular interactions, play a pivotal role in determining both MSC biology (survival, proliferation, and specific differentiation) and eventually a clinical measurable improvement.
Fusion
Cell fusion is a process that has an important biological role in the development, physiology and disease of multicellular organisms. For example, we have the zygote formation and organogenesis of various tissues, such as placenta, bone and skeletal muscle. There are different types of cell fusion: homotypic and heterotypic cell fusion. Homotypic fusion happens between cells of the same type; like fusion between myoblasts for the formation and growth of multinuclear myofibres and multinucleated cells during chronic inflammatory conditions. In a heterotypic cell fusion, which describes the fusion between cells of different lineages, we have stem cells, where in specific adult stem cells can be used for clinical therapy by introducing a nuclei or functional genes in aged or degenerating cells (79) . Recent reports have indicated that stem cells can fuse with differentiated cells in a range of tissues, including the brain, kidney, heart, lung and liver. It's known that inflammation promotes migration and infiltration of bone marrow-derived stem cells to sites of tissue injury. Moreover, inflammation also increases the frequency of stem cell fusion. In the brain, chronic inflammation cen cause an increase in spontaneous fusion events through the increase of cytokine levels, by activating immune cells or by damaging the blood brain barrier leading to increased permeability (80, 81 However, additional studies in animal models will be required to determine whether this fusion can be used in reparative cell therapy.
Paracrine factors
Although there are many ways through which stem cells may ameliorate injury, the main mechanism is considered is through paracrine and endocrine functions. Today, a wide range of cytokines and factors are known to be involved in the beneficial interaction between MSC and other cells.
Immunomodulation
Among all theories regarding the paracrine action for MSCs, by far the most explored and discussed by research is immunomodulation. Considering the inflammatory nature of most injuries, studies have indicated that the predominant role of MSCs in resolving tissue damage relies on toning down inflammation in specific sites of injury. While there are many factors suggested by literature, the main and most frequently pointed out factors and regulated immune cells are discussed ahead.
Monocytes/Macrophages
Since macrophages are one of the main cells responsible for cytokine production in injury sites, these cells are main focus points when immunomodulation is considered. Recent studies have indicated an important role in mesenchymal stem cell monocyte and macrophage immunomodulation. Maggini et al. amongst others have demonstrated that MSCs inhibit macrophage pro-inflammatory cytokine production, i.e. TNF-a, IL-6 and IFN-g (87-89). MSC also stimulate anti-inflammatory cytokine, IL-10 and IL-12p40 production (87, 88) . This way, immune cell activation and the local inflammatory process is contained, reducing tissue damage. MSC also enhance apoptotic cell phagocytosis which is important in clearing injury sites. In addition, these cells inhibit monocyte derived dendritic cell differentiation (90) . These effects seem to be due mainly to MSC-derived PGE2 secretion, which has direct effects on macrophage activation.
Dendritic Cells
Dendritic cells (DCs) have essential roles in antigen presentation and lymphocyte profile modulation. MSC are capable of inhibiting DC maturation through cell to cell contact and PDGE2 and IL-6 production, as seen through downregulated expression of CD1a, IL-12p70, MHC class II molecules, CD80 and CD86 (91, 92) . As T cells depend importantly on antigen presenting cells to become activated, dendritc cell modulation is considered a possible mechanism for T lymphocyte tolerance induction. In addition, MSC treatment also impacts DC migration, as seen in reduced CCR7 expression and reduced migration in response to CCL19 (92) . Also, mature type 1 DCs decrease TNF-a production and type 2 DCs increase IL-10 expression which may also induce Th2 profile lymphocytes (93).
T Lymphocytes
Research has shown that T lymphocyte modulation has an important role in the therapeutic character of MSC. For starters, in a disease setting, a considerable percentage of exogenous MSCs tend to accumulate in the spleen and lymph nodes, in particular around immune cells such as DCs, T and B lymphocytes, suggesting cell-specific interaction (94) . MSCs are not considered to display important allogenic properties, being immune-privileged, due to low HLA -DR and costimulatory molecule expression and its basic immunomodulatory properties, although a full consensus does not exist towards the degree in which this happens (95, 96) . In vitro, MSC inhibit phytohemagglutinin mitogen-induced and mixed lymphocyte reaction allo-antigen driven T cell proliferation (97) (98) (99) . This is done by both cell-to-cell contact and humoral factors in specific, secreting IDO and Galectin-1. These stem cells also decrease TNF-a and IFN-g T cell production and raise IL-10 secretion, possibly mediated by IDO, PGE2 and B7-H amongst other molecules (100-102). MSCs also induce Th2 type lymphocyte and T regulatory cell differentiation through, HLA-G5 and other molecules (103) (104) (105) (107, 108) . On the other hand, other studies indicate that mesenchymal stem cells induce B-cell proliferation and differentiation into plasmocytes, when stimulated with a Toll-like receptor 9 agonist (109). These different results are probably due to the different stimuli used and its detailed effect on B cell outcome is still to be discovered.
NK / iNKT Cells
Little information is still known on MSC-mediated NK / invariant natural killer T Cells (iNKT) in comparison to other cell types. Studies demonstrate that MSCs inhibit NK and iNKT cell activation and IFN-g production by secretion of mediators as HLA-G5 and PGE2 respectively (110, 111) . It is also important to mention that NK cells induce MSC lysis, probably due to low HLA class I molecule expression (112, 113) . Also, important consideration needs to be given to MSC effects on the immune system in regards to tumor surveillance, due to NK cell inhibition (114).
Angiogenic factors
Angiogenic support provided by MSC can be considered one more supportive effect, since the re-establishment of blood supply is fundamental for recovery of damaged tissues. The pro-angiogenic effect of MSC have been demonstrated in several studies in vitro and in vivo (115) (116) (117) (118) . It is known that MSCs express and secrete Stromal cell-derived factors 1 (SDF-1), vascular endothelial growth factor (VEGF), and other cytokines important for angiogenesis (Basic Fibroblast Growth Factor (bFGF); Matrix metalloproteinases (MMPs). VEGF has been identified as a key component in the development of blood vessels, but VEGF alone may be insufficient to achieve functional and mature development of the vasculature. VEGFinduced vessels are often leaky and do not connect appropriately to the existing vasculature (119, 120) . SDF-1 activity is essential for endothelial cell survival, vascular branching and pericyte recruitment (121) . Interestingly, SDF-1a is not only a mobilization signal capable of recruiting CXCR4-positive progenitor cells into hypoxic tissues but also a retention signal for angiocompentent bone marrow-derived stem cells. It also recruits pericytes and smooth muscle cells to stabilize and mature newly formed blood vessels (122, 123) . Thus, SDF-1 has been shown to augment neovascularization by the acceleration of endothelial progenitor cell (EPC) recruitment into ischemic foci (122, 124) . In addition, VEGF is one of the powerful angiogenic cytokines that can also mobilize EPCs from bone marrow and inhibit EPC apoptosis (125) . In the mouse ischemic hind limb model, VEGF-A-mediated angiogenesis partly depends on the activation of the SDF-1-CXCR4 pathway (124) . Taken together, the chemokine SDF-1 likely plays a pivotal role in ASC-mediated angiogenesis (126) . Interestingly, studies have demonstrated that mesenchymal stem cells have the same angiogenesis property. Shintani et al demonstrated that implantation of autologous bone marrow mononuclear cells into ischemic skeletal muscles successfully augmented angiogenesis and collateral vessel formation in both animal studies and human trials (127) (128) (129) . The same group found that implantation of ASC significantly augmented angiogenesis in a mouse model of hind limb ischemia, by release chemokines such as SDF-1 (126) . Kim et al. demonstrated in a preliminary clinical trial that implantation of human cord blood-derived mesenchymal stem cells enhanced angiogenesis and collateral vessel formation in human cases with Buerger's disease (130) . Kamihata and colleagues h a v e r e p o r t e d t h a t b o n e m a r r o w m o n o n u c l e a r c e l l s t h a t s u r v i v e d e n g r a f t i n g c a n synthesize angiogenic factors such as VEGF, bFGF, and angiopoietin-1 to induce angiogenesis in the ischemic myocardium (128) . In summary, engrafting MSC in clinical therapy has a beneficial effect, which may be attributable to paracrine action. MSC secrete a number of angiogenic factors and stem cell homing factor that are able to re-establishment of blood supply, being this fundamental for the recovery of damaged tissues.
Anti-apoptotic factors
An important role in MSC-mediated protection is its inhibition of tissue apoptosis and augmentation of tissue turnover. Studies show that MSC are capable of inhibiting apoptosis in kidney, liver and brain injuries (30, (131) (132) (133) . Recent evidence shows that this is done through increasing prosurvival factors as Akt expression in injured cells (55), BDNF and growth factors as IGF, VEGF and HGF expression which inhibit apoptosis and stimulate cell proliferation (134, 135) . Together, this dynamic permits high cell turn-over, renewing damaged cells and decreasing excessive cell death, thus restoring normal tissue physiology.
Anti-oxidative factors
It is well known that MSC mediate tissue repair through paracrine mechanisms. Besides mediating directly in the inflammatory process, some studies have suggested that MSC also posses anti-oxidative characteristics. MSC have been observed to produce many antioxidative mediators such as IGF, PDGF, superoxide dismutase (SOD), HGF and IL-6 (136) (137) (138) (139) . MSC-conditioned media has also been seen to contain these anti-oxidative factors including G-CSF, GM-CSF and IL-12, as reviewed by Kim et al (140) . In addition, evidence has supported that MSC and its conditioned media respectively decrease oxidative damage in culture when fibroblast cells are exposed to oxidative damage-inducing environments such as UVB (141) or tert-butyl hydroperoxide (tbOOH) (142) . In addition, research indicates that MSC posses not only considerable ability to support oxidative stress by producing anti-oxidative mediators, but may actually be stimulated by hipoxia-induced ROS (reactive oxigen species). During oxidative stress, MSC seem to have increased proliferation and migration mediated by the Akt and Erk pathways and plateletderived growth factor receptor-β (PDGFR-β) phosphorylation (143, 144) . This however is still controversial. Other studies indicate that oxidative stress correlates with MSC senescence (145, 146) . These different results may be consequent to different ROS inductors, and consequently, different levels of ROS production and enviromental contributing factors envolved.
Microvesicles and miRNA
The paracrine action of MSC is now well accepted. In this sense, administration of conditioned medium of stem cell in an animal model of kidney injury has demonstrated to improve in clinical parameter outcomes correlated with decreased apoptosis and ameliorated histological parameters. Despite the bioactive molecules secreted by MSC, Bruno et al have showed that inside the conditioned medium also there are some microvesicules. These microvesicles (MVs) are circular membranes fragments that shed from the cell surface membrane carrying protein and lipids from the membranes of the cells from which they originate. Besides this, MVs may also carry mRNA and microRNA stablishing a communication between one cell and another (147) . Shedding of microvesicles is a physiologic process, however some stress conditions lead to an increase in the number of MV shed (148). Camussi's group has described that mesenchymal stem cells are able to shed microvesicles, and moreover, these MVs carry mRNA and microRNA leading to amelioration of acute and chronic experimental models of renal injury, accelerating regeneration of hepatectomized rats and activating endothelial cells (30, (149) (150) (151) .
Long term aspects of MSC therapy: cancer, immunosuppression or maldifferentiation?
The majority of pre-clinical and clinical studies, which are going on, are incipient. They analyzed the results of treatment in few months or years, not allowing long-term analysis. In these early results, MSC therapy has not shown adverse effects, being designated safe by FDA (152) . Thus it is difficult to tell if MSC treatment per se may lead to cancer. Nevertheless, several studies have showed that MSC after infusion do not engraft in any tissue, emphasizing the paracrine mechanism of action (152) . However, if the treatment is continuous or the MSC administration is repeated, MSC can be found in the injured tissue (32) . When MSC is engrafted or even when there is an in situ administration, MSC may maldifferentiate. In a model of glomerulonephritis, MSC maldifferentiate to adipose cells in the kidney (35) . In situ administration of human autologous stem cell therapy in a patient with lupus nephritis has induced angiomyeloproliferative lesions at the sites of injection and hematuria (153) . All bioactive molecules secreted by MSC are prone to stimulate cancer cells to proliferate and migrate. Some works correlate MSC to suppression of tumor growth, others to supporting it. Several questions may be related to its discrepancy: animal host, timing of injection of MSC, differences in tumor models, etc (154) . In addition, MSC may differentiate to tumor associated fibroblast (TAF), cells that support tumor growth (155) . Thus, MSC therapy should exclude patients with cancer family history. Also, the immunossupression level of MSC therapy cannot be controlled. Once MSC are injected endovenously, immunossupression is achieved. MSC therapy may compromise the host's defense against infections agents (156).
Final considerations
Many advances have been made in the field of mesenchymal stem cells. Nowadays much is known about what the MSC is and how is the mechanism of action. Currently, existing therapies administered exogenous MSC to treat several diseases. Perhaps, a deeper knowledge on endogenous stem cells may bring advances on cell therapy. To activate endogenous stem cells, via stimulation of the niche is an interesting therapeutic perspective. In addition, try to understand what happens to this endogenous stem cell in pathological state is one of the highlights to be discovered. In the conventional therapy -administration of exogenous MSC -many issues are yet to be solved: amount of injected MSC, the best route of administration, the culture conditions which are not standardized with the use of materials of animal origin, which is the best source for these cells, etc. In conclusion, the field of MSC is very fruitful and still requires to be further studied.
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